Tamer I. Khayal Sells 3,142 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) insider Tamer I. Khayal sold 3,142 shares of the firm’s stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $65.07, for a total transaction of $204,449.94. Following the completion of the transaction, the insider now directly owns 1,300 shares in the company, valued at $84,591. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

TransMedics Group Trading Down 0.7 %

Shares of NASDAQ TMDX traded down $0.46 during midday trading on Wednesday, reaching $66.97. 250,699 shares of the stock were exchanged, compared to its average volume of 333,119. The business has a 50-day simple moving average of $59.59 and a two-hundred day simple moving average of $50.37. The company has a market capitalization of $2.14 billion, a price-to-earnings ratio of -44.91 and a beta of 1.58. TransMedics Group, Inc. has a 12 month low of $10.00 and a 12 month high of $68.43. The company has a debt-to-equity ratio of 0.31, a current ratio of 12.11 and a quick ratio of 11.21.

TransMedics Group (NASDAQ:TMDX – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.15. The company had revenue of $25.68 million for the quarter, compared to analysts’ expectations of $18.96 million. TransMedics Group had a negative net margin of 58.78% and a negative return on equity of 46.03%. As a group, equities research analysts expect that TransMedics Group, Inc. will post -1.3 EPS for the current year.

Institutional Investors Weigh In On TransMedics Group

Institutional investors have recently added to or reduced their stakes in the stock. MinichMacGregor Wealth Management LLC bought a new stake in TransMedics Group in the 4th quarter valued at $42,000. MCF Advisors LLC bought a new stake in TransMedics Group in the 3rd quarter valued at $43,000. Royal Bank of Canada lifted its position in TransMedics Group by 643.0% in the 3rd quarter. Royal Bank of Canada now owns 1,122 shares of the company’s stock valued at $46,000 after acquiring an additional 971 shares in the last quarter. Prospera Financial Services Inc bought a new stake in TransMedics Group in the 2nd quarter valued at $69,000. Finally, Tower Research Capital LLC TRC lifted its position in TransMedics Group by 125.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,603 shares of the company’s stock valued at $109,000 after acquiring an additional 1,448 shares in the last quarter. 88.58% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

TMDX has been the topic of a number of recent research reports. Canaccord Genuity Group raised their price objective on shares of TransMedics Group from $58.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, November 4th. Cowen raised their price objective on shares of TransMedics Group from $60.00 to $70.00 in a research note on Friday, December 16th. Finally, Morgan Stanley raised their price objective on shares of TransMedics Group from $54.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, January 6th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $53.29.

About TransMedics Group

(Get Rating)

TransMedics Group, Inc operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.